Health

2023-11-29 03:44:30

This is encouraging news on the front of the fight once morest Like. The number of HIV tests continued to increase in 2022, exceeding the level of 2019, before the Covid-19a result “encouraging regarding the dynamics of the epidemic”, even if the evolution is contrasted depending on the populations, notes Public Health France on Tuesday.

In 2021, screening had started to increase once more but had not yet caught up with the delay linked to Covid-19, which represented a loss of opportunity for some patients. Last year, the number of tests for HIV and the three IS bacteria continued to increase.

6.5 million HIV serologies carried out by laboratories

Some 2.6 million people have thus benefited at least once from reimbursed screening for Chlamydia trachomatis infection, 3 million from screening for gonococcal infection and 3.1 million from screening for syphilis. HIV screening activity reached a higher level than in 2019 with 6.5 million HIV serologies carried out by laboratories (compared to 6.34 million three years before).

The number of people who discovered their HIV status in 2022 was estimated between 4,200 and 5,700, numbers lower than those in 2019, which, “in a context of an increase in the volume of screening, is encouraging in terms of the dynamics of the epidemic,” notes the public health agency.

However, a “contrasting” development

However, “the evolution is contrasted depending on the populations,” she adds. Thus, the number of HIV discoveries continues to decrease among men who have sex with men (MSM) born in France: they represent 27% of HIV discoveries in 2022. This decrease observed since 2016 is probably explained by the increasing adoption of PrEP (pre-exposure prophylaxis, preventive pill for people very exposed to HIV) in this population, underlines Public Health France. Conversely, the number of discoveries continues to increase among MSM born abroad.

More than half of the discoveries in 2022 (56%) concerned people born abroad, whether they were contaminated by heterosexual relations or by sexual relations between men, hence the importance of guaranteeing them “access to care and to intensify preventive actions towards them,” underlines the agency. “Many means are available to protect oneself and others, including PrEP which is still insufficiently used by eligible people,” commented Dr. Caroline Semaille, general director of the agency.

World AIDS Day this December 1st

On the occasion of World AIDS Day on Friday, Public Health France is deploying the second part of the “Everyone asks questions regarding sexuality” campaign dedicated to STIs and HIV, the objective of which is to encourage the use of combined prevention and screening.

20 Minutes with AFP

1701230629
#Screenings #rise #exceeding #level

2023-11-28 22:31:00

(Adds comments from Sanofi and clarifies that vaccinations are intended for children) by Susan Heavey and Ahmed Aboulenein

Senior Biden administration officials met with makers of children’s RSV vaccines this week to emphasize the need for manufacturers such as Sanofi

SASY.PA and AstraZeneca AZN.L to urgently meet demand as winter approaches, the White House said Tuesday.

At a White House meeting Monday, officials and manufacturers also agreed to plan now to meet demand for vaccines once morest respiratory syncytial virus, which typically causes mild symptoms similar to those cold, but can develop into serious illness in infants and older adults.

“Monday’s meeting follows numerous in-person and virtual meetings aimed at finding ways for manufacturers to make more RSV vaccines available to infants,” the White House said in a statement.

“We, along with our manufacturing partner AstraZeneca, remain in close contact with the Centers for Disease Control and Prevention and the Food and Drug Administration, as well as the White House, to explore solutions to respond to this exceptional demand and to actively plan for the 2024-2025 season,” a Sanofi spokesperson said in an emailed statement.

Separately, the US Centers for Disease Control and Prevention said it has accelerated the availability of more than 77,000 additional doses of Beyfortus, Sanofi and AstraZeneca’s RSV drug, which was approved early in the year. year to prevent illness in infants and young children.

RSV cases in the United States began a sharp upward trend in mid-October and reached their highest level since January of last winter, with 4,952 cases detected by testing during the week. which ended on November 4, according to the CDC website.

1701229316
#White #House #urges #RSV #vaccine #makers #meet #demand #p.m